Prolonged function of macrophage, von Willebrand factor-deficient porcine pulmonary xenografts

American Journal of Transplantation

Volumn 7, Issue 1, 2007, Pages 66-75

  Cantu, E ^a   Balsara, K R ^a   Li, B ^a   Lau, C ^a   Gibson, S ^a   Wyse, A ^a   Baig, K ^a   Gaca, J ^a   Gonzalez Stawinski, G V ^a   Nichols, T ^b   Parker, W ^a   Davis, R D ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Lung transplant; VWF; Xenograft

Indexed keywords

VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CELL FUNCTION; CONTROLLED STUDY; EVALUATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; DELAYED GRAFT FUNCTION; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; MACROPHAGES, ALVEOLAR; MODELS, ANIMAL; PAPIO; SWINE; TRANSPLANTATION, HETEROLOGOUS; VON WILLEBRAND FACTOR;

EID: 33845614473     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01603.x     Document Type: Article

References (62)

1. Pierson RN, III, Tew DN, Konig WK, Dunning JJ, White DJ, Wall-work J. Pig lungs are susceptible to hyperacute rejection by human blood in a working ex vivo heart-lung model. Transplant Proc 1994; 26(3): 1318.
2. Pierson RN, III, Dunning JJ, Konig WK et al. Mechanisms governing the pace and character of pig heart-lung rejection by human blood. Transplant Proc 1994; 26(4): 2337.
3. Pierson RN, III, Kasper-Konig W, Tew DN et al. Hyperacute lung rejection in a pig-to-human transplant model: The role of antipig antibody and complement. Transplantation 1997; 63(4): 594-603.
4. Macchiarini P, Mazmanian GM, Oriol R et al. Ex vivo lung model of pig-to-human hyperacute xenograft rejection. J Thorac Cardiovasc Surg 1997; 114(3): 315-325.
5. Daggett CW, Yeatman M, Lodge AJ et al. Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion model. J Thorac Cardiovasc Surg 1997; 113(2): 390-398.
6. Yeatman M, Daggett CW, Parker W et al. Complement-mediated pulmonary xenograft injury: Studies in swine-to-primate orthotopic single lung transplant models. Transplantation 1998; 65(8): 1084-1093.
7. Pierson RN, III, Pino-Chavez G, Young VK, Kaspar-Konig W, White DJ, Wallwork J. Expression of human decay accelerating factor may protect pig lung from hyperacute rejection by human blood. J Heart Lung Transplant 1997; 16(2): 231-239.
8. Macchiarini P, Oriol R, Azimzadeh A et al. Evidence of human non-alpha-galactosyl antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. J Thorac Cardiovasc Surg 1998; 116(5): 831-843.
9. D'Apice AJ, Cowan PJ. Profound coagulopathy associated with pig-to-primate xenotransplants: How many transgenes will be required to overcome this new barrier? Transplantation 2000; 70(9): 1273-1274.
10. Gaca JG, Lesher A, Aksoy O et al. Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. Transplantation 2002; 73(11): 1717-1723.
11. Coller BS, Hirschman RJ, Gralnick HR. Studies on the Factor VIII/von Willebrand factor antigen on human platelets. Thromb Res 1975; 6(6): 469-480.
12. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. J Cell Biol 1984; 99(6): 2123-2130.
13. Pareti FI, Fujimora Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem 1986; 261: 15310-15315.
14. O'Brien JR. Shear induced platelet aggregation. Lancet 1990; 335: 711-713.
15. Howard MA, Firkin BG. Ristocetin: A new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-369.
16. Inbal A, Loscalo J. Glycocalicin binding to von Willebrand Factor adsorbed onto collagen-coated or polystyrene surfaces. Thromb Res 1989; 56: 347-357.
17. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. Von Willebrand factor binding to platelet GPIb initiates signals for platelet activation. J Clin Invest 1991; 88: 1568-1573.
18. Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270(40): 23352-23361.
19. Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost 1999; 82(2): 576-584.
20. Mazzucato M, De Marco L, Pradella P, Masotti A, Pareti FI. Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx. Thromb Haemost 1996; 75(4): 655-660.
21. Pareti FI, Mazzucato M, Bottini E, Mannucci PM. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br J Haematol 1992; 82(1): 81-86.
22. Holzknecht ZE, Coombes S, Blocher BA et al. Immune complex formation after xenotransplantation : Evidence of type III as well as type II immune reactions provide clues to pathophysiology. Am J Pathol 2001; 158(2): 627-637.
23. Winkler GC, Cheville NF. Postnatal colonization of porcine lung capillaries by intravascular macrophages: An ultrastructural, morphometric analysis. Microvasc Res 1987; 33(2): 224-232.
24. Staub NC. Pulmonary intravascular macrophages. Annu Rev Physiol 1994; 56: 47-67.
25. Brain JD, Molina RM, DeCamp MM, Warner AE. Pulmonary intravascular macrophages: Their contribution to the mononuclear phagocyte system in 13 species. Am J Physiol 1999; 276(20): L146-L154.
26. Miyamoto K, Schultz E, Heath T, Mitchell MD, Albertine KH, Staub NC. Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. J Appl Physiol 1988; 64(3): 1143-1152.
27. Chitko-McKown CG, Chapes SK, Brown RE, Phillips RM, McKown RD, Blecha F. Porcine alveolar and pulmonary intravascular macrophages: Comparison of immune functions. J Leukoc Biol 1991; 50(4): 364-372.
28. Bertram TA, Overby LH, Danilowicz R, Eling TE, Brody AR. Pulmonary intravascular macrophages produce prostaglandins and leukotrienes in vitro. Chest 1988; 93(3 Suppl): 82S-84S.
29. Collins BJ, Blum MG, Parker RE et al. Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. J Appl Physiol 2001; 90(6): 2257-2268.
30. Tector AJ, Fridell JA, Watanabe T et al. Pulmonary injury in recipients of discordant hepatic and renal xenografts in the dog-to-pig model. Xenotransplantation 1998; 5(1): 44-49.
31. van Rooijen N. The liposome-mediated macrophage 'suicide' technique. J Immunol Methods 1989; 124(1): 1-6.
32. van Rooijen N. Liposome-mediated elimination of macrophages. Res Immunol 1992; 143(2): 215-219.
33. Sone Y, Nicolaysen A, Staub NC. Effect of particles on sheep lung hemodynamics parallels depletion and recovery of intravascular macrophages. J Appl Physiol 1997; 83(5): 1499-1507.
34. Sone Y, Serikov KB, Staub NC. Intravascular macrophage depletion attenuates endotoxin in lung injury in anesthetized sheep. J Appl Physiol 1999; 87(4): 1354-1359.
35. Cantu IIIE, Gaca JG, Palestrant D et al. Depletion of Pulmonary Intravascular Macrophages Prevents Hyperacute Pulmonary Xenograft Dysfunction. Transplantation 2006; 81(8): 1157-1164.
36. Gaca JG, Palestrant D, Lukes DJ, Olausson M, Parker W, Davis RD, Jr. Prevention of acute lung injury in swine: Depletion of pulmonary intravascular macrophages using liposomal clodronate. J Surg Res 2003; 112(1): 19-25.
37. Diamond LE, Byrne GW, Schwarz A, Davis TA, Adams DH, Logan JS. Analysis of the control of the anti-gal immune response in a non-human primate by galactose alpha1-3 galactose trisaccharide-polyethylene glycol conjugate. Transplantation 2002; 73(11): 1780-1787.
38. Gonzalez-Stawinski GV, Daggett CW, Lau CL et al. Non-anti-Gal alpha 1-3 Gal antibody mechanisms are sufficient to cause hyperacute lung dysfunction in pulmonary xenotransplantation. J Am Coll Surg 2002; 194(6): 765-773.
39. Platt JL, Turman MA, Noreen RJ, Fischel RJ, Bolman RM, Bach FH. An ELISA assay for xenoreactive natural antibodies. Transplantation 1990; 49: 1000-1001.
40. Esmon C. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348.
41. Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 1988; 18(4-6): 328-341.
42. Lau CL, Daggett WC, Yeatman MF et al. The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants. J Thorac Cardiovasc Surg 2000; 120(1): 29-38.
43. Rabinovici R, Yeh CG, Hillegass LM et al. Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 1992; 149(5): 1744-1750.
44. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201(6): 871-879.
45. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999; 94(10): 3413-3420.
46. Yan SF, Zou YS, Gao Y et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A 1998; 95: 8298-8303.
47. Lawson CA, Yan SD, Yan SF et al. Monocytes and tissue factor promote throbosis in amurine model of oxygen deprivation. J Clin Invest 1997; 90(7): 1729-1738.
48. Tracy PB, Allen DH, Worfolk LA, Lawler RR. Monocyte/macrophage regulation of coagulant events. Haemostasis 1996; 26(Suppl 1): 6-11.
49. Compeau CG, Ma J, DeCampos KN et al. In situ ischemia and hypoxia enhance alveolar macrophage tissue factor expression. Am J Respir Cell Mol Biol 1994; 11(4): 446-455.
50. Taylor FB, Jr., Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33(3): 127-134.
51. Salom RN, Maguire JA, Hancock WW. Endothelial activation and cytokine expression in human acute cardiac allograft rejection. Pathology 1998; 30(1): 24-29.
52. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002; 43(2): 117-125.
53. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat Med 2003; 9(4): 458-462.
54. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96(12): 1233-1239.
55. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr., Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171(4): 1363-1368.
56. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73(1): 159-165.
57. Robson SC, Kaczmarek E, Siegel JB et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185(1): 153-163.
58. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77(2): 394-398.
59. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79(1): 124-130.
60. Lawson JH, Platt JL. Molecular barriers to xenotransplantation. Transplantation 1996; 62(3): 303-310.
61. Siegel JB, Grey ST, Lesnikoski BA et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64(6): 888-896.
62. nd, Robson SC et al. O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation 2005; 12: 30-37.